Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Novel Resistance Mutations to ALK Tyrosine Kinase Inhibition Arising During Cell‐Culture Drug Selections in T‐Cell Lymphoma

View through CrossRef
Anaplastic Large Cell Lymphoma (ALCL) is a rare T‐cell lymphoma. The Anaplastic Lymphoma Kinase (ALK)‐positive molecular subtype of ALCL is driven by constitutive activation of the ALK tyrosine‐kinase domain, typically through chromosomal translocation. The most common rearrangement, t(2;5)(p23;q35), results in the NPM‐ALK fusion kinase. Recently, two ALK‐specific tyrosine kinase inhibitors (TKIs), crizotinib and ceritinib, have been approved for clinical use in ALK‐positive lung cancer while another inhibitor, alectinib, is in early‐stage clinical trials. We developed TKI‐resistant ALK + ALCL cell line subclones from Karpas‐299, SUP‐M2 and SU‐DHL‐1. Each line was cultured in increasing concentrations of crizotinib or ceritinib until viable at 500nM and 150nM, respectively. We identified three novel mutations in our resistant lines affecting the ALK kinase domain: R1192P, I1171S, and F1174L. We cloned wild‐type and mutant NPM‐ALK into a murine retroviral vector and infected an IL3‐dependent murine pro‐B cell line FL5‐12. The infected lines were withdrawn from IL‐3, leading to their IL3‐independent, oncogene‐dependent transformation. We evaluated the half‐maximal inhibitory concentration (IC 50 ) of crizotinib, ceritinib and alectinib for wild‐type ALK‐dependent and mutant ALK dependent FL5‐12 cells, through luminescence based viability assays (Table 1). We found that all three mutations confer resistance to both crizotinib and ceritinib to varying degrees. I1171S was the only mutation to confer resistance to alectinib, while R1192P and F1174L remain sensitive. Our findings have significant clinical implications in matching specific TKIs to patient disease based on ALK mutational status. NPM‐ALK Genotypes Average Crizotinib IC 50 (nM) Crizotinib Standard Error of the Mean Average Ceretinib IC 50 (nM) Ceretinib Standard Error of the Mean Average Alectinib IC 50 (nM) Alectinib Standard Error of the Mean Wild Type 171.85 7.19 34.03 2.00 2.84 .33 R1192P 366.8 17.56 97.19 5.40 5.47 .29 I1171S 479.825 28.9 57.7 1.24 43.185 4.34 F1174L 245.05 15.9 57.015 3.62 3.87 .68
Title: Novel Resistance Mutations to ALK Tyrosine Kinase Inhibition Arising During Cell‐Culture Drug Selections in T‐Cell Lymphoma
Description:
Anaplastic Large Cell Lymphoma (ALCL) is a rare T‐cell lymphoma.
The Anaplastic Lymphoma Kinase (ALK)‐positive molecular subtype of ALCL is driven by constitutive activation of the ALK tyrosine‐kinase domain, typically through chromosomal translocation.
The most common rearrangement, t(2;5)(p23;q35), results in the NPM‐ALK fusion kinase.
Recently, two ALK‐specific tyrosine kinase inhibitors (TKIs), crizotinib and ceritinib, have been approved for clinical use in ALK‐positive lung cancer while another inhibitor, alectinib, is in early‐stage clinical trials.
We developed TKI‐resistant ALK + ALCL cell line subclones from Karpas‐299, SUP‐M2 and SU‐DHL‐1.
Each line was cultured in increasing concentrations of crizotinib or ceritinib until viable at 500nM and 150nM, respectively.
We identified three novel mutations in our resistant lines affecting the ALK kinase domain: R1192P, I1171S, and F1174L.
We cloned wild‐type and mutant NPM‐ALK into a murine retroviral vector and infected an IL3‐dependent murine pro‐B cell line FL5‐12.
The infected lines were withdrawn from IL‐3, leading to their IL3‐independent, oncogene‐dependent transformation.
We evaluated the half‐maximal inhibitory concentration (IC 50 ) of crizotinib, ceritinib and alectinib for wild‐type ALK‐dependent and mutant ALK dependent FL5‐12 cells, through luminescence based viability assays (Table 1).
We found that all three mutations confer resistance to both crizotinib and ceritinib to varying degrees.
I1171S was the only mutation to confer resistance to alectinib, while R1192P and F1174L remain sensitive.
Our findings have significant clinical implications in matching specific TKIs to patient disease based on ALK mutational status.
NPM‐ALK Genotypes Average Crizotinib IC 50 (nM) Crizotinib Standard Error of the Mean Average Ceretinib IC 50 (nM) Ceretinib Standard Error of the Mean Average Alectinib IC 50 (nM) Alectinib Standard Error of the Mean Wild Type 171.
85 7.
19 34.
03 2.
00 2.
84 .
33 R1192P 366.
8 17.
56 97.
19 5.
40 5.
47 .
29 I1171S 479.
825 28.
9 57.
7 1.
24 43.
185 4.
34 F1174L 245.
05 15.
9 57.
015 3.
62 3.
87 .
68.

Related Results

The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study
The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study
Background: Anaplastic large cell lymphomas (ALCLs) represent a heterogeneous group of T-cell lymphomas that currently are classified by the presence or absence of ALK tyrosine kin...
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Primary Thyroid Non-Hodgkin B-Cell Lymphoma: A Case Series
Abstract Introduction Non-Hodgkin lymphoma (NHL) of the thyroid, a rare malignancy linked to autoimmune disorders, is poorly understood in terms of its pathogenesis and treatment o...
Exploring the Association between Lymphoma and Inflammatory Bowel Disease in an Inner-City Academic Institution
Exploring the Association between Lymphoma and Inflammatory Bowel Disease in an Inner-City Academic Institution
Introduction: The incidence of lymphoma has been increasing over the past several decades, with data showing an estimated annual percentage change of 0.56%. There...
Data from SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma
Data from SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma
<div>Abstract<p>Survival rates among patients with high-risk neuroblastoma remain low and novel therapies for recurrent neuroblastomas are required. <i>ALK</i&...
Data from SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma
Data from SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma
<div>Abstract<p>Survival rates among patients with high-risk neuroblastoma remain low and novel therapies for recurrent neuroblastomas are required. <i>ALK</i&...
Role of the mutated ALK oncogene in neuroblastoma oncogenesis and in development
Role of the mutated ALK oncogene in neuroblastoma oncogenesis and in development
Rôle de l’oncogène ALK muté dans l’oncogenèse du neuroblastome et le développement Le neuroblastome (NB) est une tumeur pédiatrique du système nerveux sympathique. ...
Abstract 6734: Identification of the novel TENM3-ALK fusion in an AYA case with ALK rearranged neuroblastoma
Abstract 6734: Identification of the novel TENM3-ALK fusion in an AYA case with ALK rearranged neuroblastoma
Abstract Neuroblastoma is the most common extracranial solid tumor that occurs in childhood and the most common cancer in infancy. Fewer than 5% of neuroblastomas oc...
Ciblage thérapeutique de ALK et de CD47 dans le lymphome anaplasique à grandes cellules ALK-positif
Ciblage thérapeutique de ALK et de CD47 dans le lymphome anaplasique à grandes cellules ALK-positif
Le lymphome anaplasique à grandes cellules ALK-positif (ALK-positive anaplastic large cell lymphoma, ALCL ALK+) est un lymphome T périphérique rare (environ 50 nouveaux cas par an ...

Back to Top